Cytokines in dementia of the alzheimer's type (DAT): Relevance to research and treatment

Neuroscience and Biobehavioral Reviews

Volumn 22, Issue 3, 1998, Pages 389-394

  Malek Ahmadi, Parviz ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid; Acute phase response; Alzheimer's disease; Cytokines; Interleukins; Neurotoxicity; Nitric oxide synthase; Transforming growth factor ; Tumor necrosis factor

Indexed keywords

AMYLOID BETA PROTEIN; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; ARTICLE; HUMAN; HUMAN TISSUE; MEDICAL RESEARCH; NEUROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; BRAIN CHEMISTRY; CYTOKINES; HUMANS;

EID: 0031900821     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(97)00027-4     Document Type: Article

References (74)

1. Aggarwal B. B., Pocsik E. Cytokines: From clone to clinic. Arch. Biochem. Biophys. 292:1992;335-359.
2. Allen S. A., Styren S. D., Rogers J. Molecular and cellular characterization of cytokines in Alzheimer disease (abstract). Soc. Neurosc. Abstr. 15:1989;329.
3. Altstiel L. D., Sperber K. Cytokines in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. 15:1991;481-495.
4. Araujo L. D., Lapchak P. A., Collier B., Quirion R. Localization of interleukin-2 immunoreactivity in the rat brain: interaction with cholinergic system. Brain Res. 498:1989;257-266.
5. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:1991;111-114.
6. Bellinger F. P., Madamba S., Siggins G. R. Interleukin 1β inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res. 628:1993;227-234.
7. Benveniste E. N., Kwon J. B., Chung W. J., Sampson J., Pandya K., Ting L-P. Differential modulation of astrocyte cytokine gene expression by TGF-β J. Immunol. 153:1994;5210-5221.
8. Bertini R., Garattini S., Delgado R., Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunology. 79:1993;217-219.
9. Blume A. J., Vitek M. P. Focusing on IL-1 promotion of β-amyloid precursor protein synthesis as an early event in Alzheimer disease. Neurobiol. Aging. 10:1989;406-408.
10. Bodmer S., Podlisny M. B., Selkoe D. J., Heid I., Fontana A. Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. Biochem. Biophys. Res. Commun. 171:1990;890-897.
11. Brugg, B.; Lemaigre-Dubreuil, Y.; Huber, G.; Kopmels, B.; Delhye-Bouchaud, N.; Wollman, E. E.; Mariani, J., Neuronal death, proinflammatory cytokines and amyloid precursor protein: Studies on staggerer mutant mice. In Kosik, K. S.; Christen, Y.; Selkoe, D. J., eds., Alzheimer's Disease: Lessons from Cell Biology. Springer-Verlag, Berlin Heidelberg, 1995, pp. 202-216.
12. Buxbaum J. D., Oishi M., Chen H. I., Pinkas-Kramarski R., Jaffe E. A., Gandy S. E., Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA. 89:1992;10075-10078.
13. Cacabelos R., Alvarez X. A., Fernandez-Novoa L., Franco A., Mangues R., Pellicer A., Nishimura T. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp. Clin. Pharmacol. 16:1994;141-151.
14. Cacabelos R., Alvarez X. A., Franco-Maside A., Fernandez-Novoa L., Caamano J. Serum tumor necrosis factor (TNF) levels in Alzheimer's disease and multi-infarct dementia. Methods Find Exp. Clin. Pharmacol. 16:1994;29-35.
15. Cunningham A. J., Murray C. A., O'Neille L. A. J., Lynch M. A., O'Conner J. J. O. Interleukin-1β (IL-1β) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci. Lett. 203:1996;17-20.
16. Donnelly R. J., Friedhoff A. J., Beer B., Blume A. J., Vitek M. P. Interleukin-1 stimulates the beta-amyloid precursor protein promoter. Cell Mol. Neurobiol. 10:1990;485-495.
17. Eddleston M., Mucke L. Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
18. Fiebich B. L., Lieb K., Hull M., Berger M., Bauer J. Effects of NSAIDs on IL-1 β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport. 7:1996;1209-1211.
19. Fillit H., Ding W., Buee L., Kalman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:1991;318-320.
20. Flanders K. C., Lippa C. F., Smith T. W., Pollen D. A., Sporn M. B. Altered expression of transforming growth factor-β in Alzheimer's disease. Neurology. 45:1995;1561-1569.
21. Forloni G., Demicheli D., Giorgi S., Bendotti C., Angeletti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells. Modulation by interleukin-1. Mol. Brain Res. 16:1992;128-134.
22. Ganter U., Strauss S., Jonas U., Weidemann A., Beyreuther K., Volk B., Berger M., Bauer J. Alpha 2-macroglobulin synthesis in interleukin-6-stimulated human neuronal (SH-SY5Y neuroblastoma) cells: potential significance for the processing of Alzheimer β-amyloid precursor protein. FEBS Lett. 282:1991;127-131.
23. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 16:1993;460-465.
24. Goldgaber D., Harris H. W., Hla T., Maciag T., Donnelly R. J., Jacobsen J. S., Vitek M. P., Gajdusek D.C. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA. 86:1989;7606-7610.
25. Graves A. B., White E., Koepsell T. D., Reifler B. V., van Belle G., Larson E. B., Raskind M. The association between head trauma and Alzheimer's disease. Am. J. Epidemiol. 131:1990;491-501.
26. Gray C. W., Patel A. J. Regulation of β-amyloid precursor protein isoform mRNAs by transforming growth factor-β-1 and interleukin-1β in astrocytes. Mol. Brain Res. 19:1993;251-256.
27. Griffin W. S. T., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L. III, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
28. Griffin W. S. T., Sheng J. G., Roberts G. W., Mrak R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
29. Hall A. K., Rao M. S. Cytokines and neurokines: related ligands and related receptors. Trends Neurosci. 15:1992;35-37.
30. Han J., Thompson P., Beutler B. Dexamethasone and pentoxyfylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172:1990;391-394.
31. Hull M., Fiebich B. L., Lieb K., Strauss S., Berger M., Volk B., Bauer J. Interleukin-6-associated inflammatory processes in Alzheimer's disease: New therapeutic options. Neurobiol. Aging. 17:1996;795-800.
32. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. (Berlin). 89:1995;544-551.
33. Itagaki S., McGeer P. L., Tago H., McGeer E. G. Expression of HLA-DR and interleukin-2 receptor on reactive micorglia in senile dementia of the Alzheimer type. Soc. Neurosci. Abst. 13:1987;366.15.
34. Khansari N., Whitten H. D., Chou Y. K., Fudenberg H. H. Immunological dysfunction in Alzheimer's disease. J. Neuroimmunol. 7:1985;279-285.
35. Kragh-Sorensen P., Olsen R. B., Lund S., Van Riezen H., Steffensen K. Neuropeptides: ACTH-peptides in dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:1986;479-492.
36. Luber-Narod J., Rogers J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci. Lett. 94:1988;17-22.
37. Maes M., Meltzer H. Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
38. Malek-Ahmadi P. Neuropsychiatric aspects of cytokines research: An overview. Neurosci. Biobehav. Rev. 20:1996;359-365.
39. 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. J. Neuroimmunol. 48:1993;235-240.
40. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
41. Meda L., Cassatella M. A., Szendrei G. I., Otvos Jr L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by β-amyloid protein and interferon-γ Nature. 374:1995;647-650.
42. Merrill J. E., Jonakait G. M. Interactions of the nervous and immune systems in development, normal brain homeostasis, and disease. Fed. Am. Soc. Exp. Biol. J. 9:1995;611-618.
43. Mire-Sluis A. R., Gaines-Das R., Thorp R. Immunoassays for detecting cytokines. What are they really measuring? J. Immunol. Methods. 186:1995;157-160.
44. Mrak R. E., Sheng J. G., Griffin W. S. T. Glial cytokines in Alzheimer's disease. Review and pathogenic implications. Hum. Pathol. 26:1995;816-823.
45. Murphy S., Simmons M. L., Agullo L., Garcia A., Feinstein D. L., Galea E., Reis D. J., Minc-Golomb D., Schwartz J. P. Synthesis of nitric oxide in CNS glial cells. Trends Neurosci. 16:1993;323-328.
46. Nitsch R. M., Slack B. E., Wurtman R. J., Growdon J. H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 258:1992;304-307.
47. Peress N. S., Perillo E. Differential expression of TGF-β1, 2 and 3 isotypes in Alzheimer's disease: A comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J. Neuropathol. Exp. Neurol. 54:1995;802-811.
48. Perlmutter L. S., Chui H. C. Microangiopathy, the vascular basement membrane and Alzheimer's disease: A review. Brain Res. Bull. 24:1990;677-686.
49. Richards, C. D.; Gauldie, J., Role of cytokines in acute-phase response. In Aggarwal, B. B.; Puri, R. K., eds. Human cytokines: Their role in disease and therapy. Blackwell Science, Cambridge, Massachussetts, 1995, pp. 253-269.
50. Rogers J., Kirby L. C., Hempelman S. R., Berry D. L., McGeer P. L., Kaszniak A. W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trials of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
51. Rothwell N. J., Hopkins S. J. Cytokines and the nervous systemII: Actions and mechanisms of actions. Trends Neurosci. 18:1995;130-136.
52. Royston M. C., Rothwell N. J., Roberts G. W. Alzheimer's disease: pathology to potential treatments? Trends Pharmacol. Sci. 13:1992;131-133.
53. Selkoe D. J. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 16:1993;403-409.
54. Sheng J. G., Mrak R. E., Griffin W. S. T. Microglial Interleukin-1a expression in brain regions in Alzheimer's disease: Correlation with neuritic plaque distribution. Neuropathol. Appl. Neurobiol. 21:1995;290-301.
55. Sheng J. G., Ito K., Skinner R. D., Mrak R. E., Rovnaghi C. R., Van Eldik L. J., Griffin W. S. T. In vivo and in vitro evidence supporting a role for inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging. 17:1996;761-766.
56. Simoni J., Simoni G., Lox C. D., Prien S. D., Shires G. T. Hemoglobin interference with an enzyme-linked immunosorbent assay for the detection of tumor necrosis factor-alpha. Anal. Chim. Acta. 313:1995;1-14.
57. Smith R. S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Medical Hypothesis. 45:1995;135-141.
58. Stevens, A.; Lowe, J. S., Histology. Gower Medical Publishing, London, 1992.
59. 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patient. Lab. Invest. 66:1992;223-230.
60. Strittmatter W.J., Saunders A.M., Schemechel D., Pericak-Vance M., Enghild J., Slavesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to β -amyloid and increased frequency of type 4 allele in late onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
61. Szabo C. Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res. Bull. 41:1996;131-141.
62. 2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17β J. Immunol. 142:1989;3134-3139.
63. Tancredi V., Zona C., Velotti F., Eusebi F., Santoni A. Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. Brain Res. 525:1990;149-151.
64. Tang M-X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
65. Terry, R. D.; Masliah, E.; Hansen, L. A., Structural basis of cognitive alterations in Alzheimer disease. In Terry, R. D.; Katzman, R.; Bick, K. L., eds. Alzheimer Disease. Raven Press, New York, 1994, pp. 179-196.
66. Unsicker K., Flanders K. C., Cissel D. S., Lafyatis R., Sporn M. B. Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience. 44:1991;613-625.
67. Vandenabeele P., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol Today. 12:1991;217-219.
68. 1 in Alzheimer and Down pathologies. Neuroreport. 4:1993;69-72.
69. vanDuijn C. M., Hofman A., Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett. 108:1990;350-354.
70. Vodovotz Y., Lucia M. S., Flanders K. C., Chesler L., Xie Q-W., Smith T. W., Weidner J., Mumford R., Webber R., Nathan C., Roberts A. B., Lippa C. F., Sporn M. B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184:1996;1425-1433.
71. Wilmot, C. A.; Sahasrabudhe, S. R.; Ringheim, G. E.; Martin, L. L.; Effland, R. C., β Amyloid, cytokines and other potential strategies for modifying the pathophysiology of Alzheimer's disease. In Cutler, N. R.; Gottfries, C. G.; Siegfried, K., eds. Alzheimer's Disease: Clinical and Treatment Perspectives. John Wiley and Sons, Chichester, 1995, pp. 115-150.
72. 2-macroglobulin and C-reactive protein. Brain Res. 629:1993;245-252.
73. Woodroofe M. N., Sarna S. S., Wadhwa M., Hayes G. M., Loughlin A. J., Tinker A., Guzner M. L. Detection of interleukin-1 and interleukin-6 in adult rat brain following mechanical injury by in vivo microdialysis: evidence of a role for microglia in cytokine production. J. Neuroimmunol. 38:1991;227-236.
74. Xu H-M., Wei J., Hemmings G. P. Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. Br. J. Psychiatry. 164:1994;251-253.